Moderna Inc
MRNA27.790USD
+0.570+2.09%
Market hours （ET）Quotes delayed by 15 min
10.73BMarket Cap
LossP/E TTM
More Details of Moderna Inc Company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
Company codeMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
Founded at2016
CEOMr. Stephane Bancel
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Company codeMRNA
IPO dateDec 07, 2018
Founded at2016
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
25.61K
+8.78%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
15.62K
+5.04%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
2.10K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Mr. Noubar Afeyan ,
Mr. Noubar Afeyan ,
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
25.61K
+8.78%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
15.62K
+5.04%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
2.10K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
COVID
3.08B
99.20%
RSV
25.00M
0.80%
By RegionUSD
Name
Revenue
Proportion
United States
1.78B
57.41%
Rest of the World
853.00M
27.44%
Europe
598.00M
19.23%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Shareholder
Update time: Thu, Mar 13
Update time: Thu, Mar 13
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
10.39%
Baillie Gifford & Co.
10.06%
Fidelity Management & Research Company LLC
4.75%
BlackRock Institutional Trust Company, N.A.
4.67%
State Street Global Advisors (US)
4.55%
Other
65.58%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
10.39%
Baillie Gifford & Co.
10.06%
Fidelity Management & Research Company LLC
4.75%
BlackRock Institutional Trust Company, N.A.
4.67%
State Street Global Advisors (US)
4.55%
Other
65.58%
Type
Shareholder
Proportion
Investment Advisor
34.33%
Investment Advisor/Hedge Fund
25.19%
Corporation
4.68%
Hedge Fund
4.51%
Research Firm
3.25%
Individual Investor
2.56%
Bank and Trust
1.73%
Pension Fund
1.55%
Venture Capital
1.20%
Other
21.01%
Institutional Shareholding
Update time: Mon, Jan 20
Update time: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
2064
320.55M
82.92%
-6.59M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
2022Q4
2442
300.08M
77.99%
-2.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
40.18M
10.39%
+101.25K
+0.25%
Dec 31, 2024
Baillie Gifford & Co.
38.89M
10.06%
-3.57M
-8.40%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.38M
4.75%
+1.28M
+7.51%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
18.04M
4.67%
+471.49K
+2.68%
Dec 31, 2024
State Street Global Advisors (US)
17.58M
4.55%
+730.02K
+4.33%
Dec 31, 2024
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Theleme Partners LLP
7.31M
1.89%
+80.00K
+1.11%
Dec 31, 2024
Geode Capital Management, L.L.C.
7.24M
1.87%
+171.77K
+2.43%
Dec 31, 2024
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
Bancel (Stephane J)
5.49M
1.42%
--
--
Mar 05, 2025
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.1%
Global X Genomics & Biotechnology ETF
2.71%
Clough Select Equity ETF
2.62%
First Trust NYSE Arca Biotechnology Index Fund
2.28%
VanEck Biotech ETF
2.05%
SPDR S&P Biotech ETF
1.82%
Langar Global HealthTech ETF
1.81%
Virtus LifeSci Biotech Products ETF
1.17%
ROBO Global Healthcare Technology & Innovation ETF
1.16%
Direxion Daily S&P Biotech Bull 3X Shares
1.15%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.1%
Global X Genomics & Biotechnology ETF
Proportion2.71%
Clough Select Equity ETF
Proportion2.62%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.28%
VanEck Biotech ETF
Proportion2.05%
SPDR S&P Biotech ETF
Proportion1.82%
Langar Global HealthTech ETF
Proportion1.81%
Virtus LifeSci Biotech Products ETF
Proportion1.17%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data